New Zealand RSV Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
New Zealand · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$43.8 MnPlaceholder estimate
Estimate 2025$49.1 Mn1.1% of the global market
Projected 2034$137.4 Mn 179.5%Adds $88.2 Mn over 9 forecast years
CAGR 2025–203412.1%Faster than 67% of 166 Pharmaceuticals markets here
1 in New ZealandSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in New Zealand. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The New Zealand RSV Vaccines Market Analysis Executive Summary
RSV vaccines protect older adults, pregnant women (for their babies) and infants against respiratory syncytial virus, a common cause of serious chest infections.
Key segments of the RSV Vaccines market include product (Older Adult Vaccines, Maternal Vaccines and Infant Monoclonal Antibodies) and age (Infants, Older Adults and Pregnant Women).
New Zealand RSV Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
New Zealand RSV Vaccines Market Dynamics
Market Growth Drivers
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the RSV Vaccines market.
Opportunity
New vaccines, rapid tests and public-private funding for neglected diseases give the RSV Vaccines market room to grow, especially in Asia, Africa and Latin America.
Market Restraints
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the RSV Vaccines market.
Competitive Landscape for RSV Vaccines Market in New Zealand
The RSV Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for RSV Vaccines Market in New Zealand
RSV Vaccines in New Zealand: rules, payment and research
Medsafe, part of the Ministry of Health, approves medicines before they can be sold.[1] Pharmac decides which medicines and medical devices the public health system pays for.[2] ClinicalTrials.gov lists 1 study on RSV Vaccines that is recruiting, active or about to start in New Zealand.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in New Zealand. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RSV Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in RSV Vaccines right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
RSV Vaccines in context
New Zealand compared
Health spending per person: 5,022 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 17 countries we cover in APAC.[1]
Doctors: 3.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 17 countries we cover in APAC.[2]
People aged 65 and over: 17.6% of people (2025). World: 10.4% of people (2025). 5th highest of the 18 countries we cover in APAC.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.
How big is the RSV Vaccines market in New Zealand?
Placeholder estimate: about $49.1 Mn in 2025, rising to about $137.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the RSV Vaccines market in New Zealand growing?
Placeholder estimate: about 12.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the RSV Vaccines market report cover?
The report splits the market by product (Older Adult Vaccines, Maternal Vaccines, Infant Monoclonal Antibodies), age (Infants, Older Adults, Pregnant Women) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the RSV Vaccines market?
Key players include GSK PLC, Pfizer Inc., Moderna, Sanofi and AstraZeneca.
What is driving the RSV Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the RSV Vaccines market.
Who regulates RSV Vaccines in New Zealand?
Medsafe, part of the Ministry of Health, approves medicines before they can be sold. Source: Medsafe. Checked 14 Nov 2026.
How is healthcare paid for in New Zealand?
Pharmac decides which medicines and medical devices the public health system pays for. Source: Pharmac. Checked 14 Nov 2026.
How many clinical trials on RSV Vaccines are running in New Zealand?
1 study is recruiting, active or about to start in New Zealand, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in New Zealand. Retrieved 12 Nov 2026.
How much research is published on RSV Vaccines?
PubMed lists 397 papers on RSV Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.